Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
about
sameAs
Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidenceSuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactionsThe effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodoneIn vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteersClinical relevance of genetic polymorphisms in the human CYP2C subfamilyIdentification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in EmiratisWhere Failure Is Not an Option -Personalized Medicine in AstronautsTolterodine use for symptoms of overactive bladder.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.Observational study of the impact of short-term duloxetine treatment on body weight in patients with major depressive disorder: a taiwanese perspectiveThe relevance of ethnic influences on pharmacogenetics to the treatment of psychosis.Pharmacogenetics and psychopharmacotherapy.Tramadol and seizures: a surveillance study in a managed care population.CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.Classics in chemical neuroscience: diazepam (valium).Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes.Cardiovascular and neurological toxicity of venlafaxine.Pharmacogenetics of the proton pump inhibitors: a systematic review.Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.Personalizing health care: feasibility and future implications.Pharmacogenomics of antimicrobial agents.Psychiatric side effects of medications prescribed in internal medicine.Sex-dependent modulation of treatment responseCytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophyllineThe xenobiotic inhibitor profile of cytochrome P4502C8.Influence of hydroxychloroquine on the bioavailability of oral metoprololA real world report on intravenous high-dose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding.
P2860
Q24608981-C9962C99-E735-4408-8E84-C5DC3F02C2ABQ24643366-118CF112-7F6B-4DB8-9842-08FD71B23793Q24669562-5EE90C6B-0C05-4689-BBFC-2D56D96206B5Q28344127-35A0471E-1149-41BA-9A7B-ED32A0140BA5Q28361031-9B21D31C-2E48-4FF7-B3CF-CB306EF574AEQ28362533-BE9DB724-A6CF-41B5-BA8A-EDE178D1ED3EQ28478547-122328C0-EDDB-4561-B1B0-6457BAC0ADC1Q28550427-37243254-17A9-4979-A68E-58BB8F12EFDAQ30799852-03DA78D9-ECC2-4180-AAFD-CF1DCB83214AQ33538523-085EE10B-30FA-417D-9291-76D9BF97ACB0Q33630990-0E1C8802-0F27-48A8-AB00-B0838E400D62Q33734852-F5B24092-E67E-4C9C-8956-D6CAAD828D17Q33902245-CA384BE5-19A5-4A26-AABE-03D8A9DC5C4FQ33924143-1D50BEC8-E81D-4229-8DB2-AEE7E67077B5Q33962212-FD6D4DC1-315F-4865-A14B-7A222C917D3AQ34113752-773E93A9-0BDC-44C3-9F2E-5417FF459150Q34125166-39E48FF9-7D27-4A60-BA93-80242395E60BQ34204238-6C68B868-6EE4-434F-9400-4FEDA1F756B0Q34269371-9EE4B65F-9180-4A31-B3B7-ECEBEBE4C8ACQ34405394-61489F0D-F927-4CF7-AE07-FF2B16C61F89Q34434069-D34E4D1B-D73F-441F-BAB8-E220753E69AFQ34503904-B35FBA1D-6DC6-4DF0-A445-FAC9D6EB9F5DQ34532600-FE678D16-0FCC-4276-8413-45A9A8924D4DQ34582043-3F6D000F-FA18-4CBC-B664-15616858E858Q34596313-05EF1E7B-6346-4DD4-9BD8-7757092F74D2Q34648742-CA1B9304-FC17-45A2-BBD1-4DAC397A6057Q34735634-7B7F64F6-BC5F-4F45-A940-10A63BB74581Q34938911-3097B549-3232-406C-AA8B-DF0914CB8E45Q34977413-F7145863-7912-44E2-9E9D-E2F4D276729BQ35236318-60D1821E-8E3F-4C5D-88F8-D74B9DBE6B42Q35236761-EF2ADB72-B600-4A32-AE43-EAAD57814B42Q35238375-20DE6911-ED5D-48A5-9591-79A8C6551F46Q35753607-B77B2F19-1E6E-4F4C-A989-9565DEED15D4Q35825489-299E779A-E138-4BC1-A5C7-76BF03B553A3Q35876954-91B74B1E-5739-4B38-8D69-EBA3E011D9E9Q36052505-AE768FFC-4E41-4A67-BCF8-5B8AE86DEA35Q36053752-2594FD33-EDAE-44BC-A501-47531B21895EQ36055384-16598E03-9A5C-4695-9A7F-7D997595628CQ36055442-85C77525-0116-44B5-9386-64F134DBF4C2Q36111706-AA245A9C-AC32-4226-BCDA-2B197A95171D
P2860
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@ast
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@en
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@nl
type
label
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@ast
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@en
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@nl
altLabel
Geographical/Interracial Differences in Polymorphic Drug Oxidation
@en
prefLabel
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@ast
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@en
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@nl
P3181
P1476
Geographical/Interracial Differences in Polymorphic Drug Oxidation
@en
Geographical/interracial diffe ...... hromes P450 (CYP) 2D6 and 2C19
@en
P2093
Leif Bertilsson
P304
P3181
P356
10.2165/00003088-199529030-00005
P407
P577
1995-09-01T00:00:00Z
P6179
1024774000